<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02230228</url>
  </required_header>
  <id_info>
    <org_study_id>ALK001-P1001</org_study_id>
    <nct_id>NCT02230228</nct_id>
  </id_info>
  <brief_title>Phase 1 Safety Study of ALK-001 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkeus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkeus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of
      ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of 4-week daily dosing of ALK-001 in healthy adults.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Safety evaluations combine: adverse events (AE), laboratory testing (hematology and biochemistry panels), 12-lead electrocardiograms (ECGs), vital signs, physical examination, and visual function (visual acuity and a self-reported questionnaire).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Stargardt Disease</condition>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Other Retinal Dystrophies</condition>
  <arm_group>
    <arm_group_label>ALK-001 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK-001 (No generic name)</intervention_name>
    <description>Daily, oral administration of ALK-001 capsules.</description>
    <arm_group_label>ALK-001 capsules</arm_group_label>
    <other_name>C20-D3-Retinyl Acetate</other_name>
    <other_name>C20 Deuterated vitamin A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria

          -  Adult between 21 and 70 years old (inclusive)

          -  Healthy subject, as judged by investigator

          -  Subject is able and willing to comply with study requirements (study medication
             compliance, schedule of follow-up visits)

          -  Subject has provided informed consent to participate

          -  If female, subject uses a medically accepted birth control method and agrees to use
             such a method for entire clinical trial period

        Main Exclusion Criteria:

          -  Subject has taken disallowed items during the past 30 days

          -  Female with a positive urine pregnancy test at screening

          -  Lactating woman

          -  Subject has participated in any clinical study involving an investigational drug,
             biologic or device, during the past 30 days

          -  History or current evidence of gastrointestinal malabsorption

          -  Subject has any other medical condition, which in the opinion of the investigator, is
             likely to prevent compliance with protocol and/or interfere with successful collection
             of study

          -  Subject has, in the opinion of investigator, clinically significant laboratory
             result(s), positive drug or alcohol screening, or ECG, which makes subject unsuitable
             for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonide Saad, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alkeus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilyas Washington, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <last_update_submitted>March 21, 2015</last_update_submitted>
  <last_update_submitted_qc>March 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

